Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102

ClinicalTrials.gov Identifier: NCT00522665.

Abstracts/Posters/Presentations:

• S. Shadha, M. Yu, J. Picus, J. Bufill, W. Harb, M. Burns, J. Spittler, J. Flynn, Y.Zeng, G. Vance, C. Currie, J. Wu, P. J. Loehrer, E.G. Chiorean. Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102, final report. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 3587). See abstract.
• Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618). See abstract.